title: The role of methotrexate in osteosarcoma.
abstract: High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic issues concerning MTX therapy in osteosarcoma are discussed.
authors.affiliation: Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
authors.forename: J L
authors.initials: JL
authors.lastname: Grem
authors.forename: S A
authors.initials: SA
authors.lastname: King
authors.forename: R E
authors.initials: RE
authors.lastname: Wittes
authors.forename: B
authors.initials: B
authors.lastname: Leyland-Jones
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery
chemical_list: D008727:Methotrexate